MedPath

南京恩泰医药科技有限公司

Ownership
-
Established
2013-04-09
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

18

NMPA:18

Drug Approvals

Composite Potassium Hydrogen Phosphate Injection

Product Name
复合磷酸氢钾注射液
Approval Number
国药准字H20254014
Approval Date
Apr 30, 2025
NMPA

Ceftazidime and Avibactam Sodium for Injection

Product Name
注射用头孢他啶阿维巴坦钠
Approval Number
国药准字H20249768
Approval Date
Dec 25, 2024
NMPA

Potassium Chloride Injection

Product Name
氯化钾注射液
Approval Number
国药准字H20249553
Approval Date
Dec 1, 2024
NMPA

Diprophylline Injection

Product Name
二羟丙茶碱注射液
Approval Number
国药准字H20244608
Approval Date
Aug 5, 2024
NMPA

Cefazolin Sodium for Injection

Product Name
注射用头孢唑林钠
Approval Number
国药准字H20247139
Approval Date
Jun 26, 2024
NMPA

Methocarbamol Injection

Product Name
美索巴莫注射液
Approval Number
国药准字H20244157
Approval Date
Jun 25, 2024
NMPA

Compound Sodium Acetate and Glucose Injection

Product Name
复方醋酸钠葡萄糖注射液
Approval Number
国药准字H20243752
Approval Date
May 21, 2024
NMPA

Compound Sodium Acetate and Glucose Injection

Product Name
复方醋酸钠葡萄糖注射液
Approval Number
国药准字H20243753
Approval Date
May 21, 2024
NMPA

Aprepitant Injection

Product Name
阿瑞匹坦注射液
Approval Number
国药准字H20234633
Approval Date
Dec 13, 2023
NMPA

Multiple Electrolytes, Sodium Acetate and Glucose Injection

Product Name
复方电解质醋酸钠葡萄糖注射液
Approval Number
国药准字H20233144
Approval Date
Feb 14, 2023
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.